As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: November 5, 2015
by Medical XPress:
An estrogen-like drug, raloxifene, has no demonstrated benefit on memory and thinking skills for women with dementia due to Alzheimer’s disease, according to a study published in the November 4, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.
“Drugs that interact with estrogen receptors have attracted a great deal of interest as a potential treatment for women with dementia due to Alzheimer’s disease, but relatively small studies of estrogen have generally failed to confirm any benefit,” said study author Victor Henderson, MD, MS, with Stanford University in Stanford, Calif., and a Fellow of the American Academy of Neurology. “Prior to this study, raloxifene had not been evaluated as an Alzheimer treatment.”
For the study, 42 women with an average age of 76 with mild to moderate dementia due to Alzheimer’s disease were separated into two groups and given raloxifene or a placebo pill for 12 months. The women were assessed on their memory and other mental functions at the start of the trial and then every three months. They were also evaluated on how well they could complete daily activities, and their family members or caregivers were asked about their caregiver burden and stress at the start, middle and end of the study.
Raloxifene is a type of drug known as a selective estrogen receptor modulator. It acts like estrogen in some parts of the body. In the uterus and breasts, raloxifene acts like an estrogen blocker. It is also used to prevent bone loss after menopause. An earlier study in healthy women suggested that raloxifene may lower the risk of cognitive impairment or dementia.
The results on the cognitive skills tests did not differ significantly between the placebo group and the group taking raloxifene. There were also no significant differences reported by family members and caregivers on the amount of caregiver burden or stress or in daily activities.
Henderson noted that the study was not designed to detect small effects from raloxifene in the range of that provided by approved Alzheimer’s drugs such as donepezil or memantine.
“We found that the drug did not have any significant effect on patients after one year,” Henderson said. “If there are cognitive effects in this population, these effects are likely to be no more than small. These results may be valuable if future trials of raloxifene are considered.”
Our bodies change as we age – partly due to natural physiological aging and partly due to lifestyle choices. As early as our thirties, we begin to lose a small amount of muscle mass, and,...
Utilizing tau PET imaging, new research finds tau to be a more accurate indication for future neurodegeneration, highlighting its potential for precision medicine-based treatment approaches. Amyloid-β has long been the bane of every Alzheimer’s researcher. Often found in...
It’s never too late to start working on brain health. That said, the strategies for how to optimize your brain will vary depending on several aspects, not the least of which is...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.